IL-6 inhibitors provide therapeutic benefits in treating COVID-19 patients
the verdict
SUPPORTED
the evidence backs this
confidence 86/100
Multiple systematic reviews and clinical studies indicate that interleukin-6 inhibitors, such as tocilizumab and sarilumab, provide therapeutic benefits and reduce mortality in patients with severe COVID-19.
Evidence for · 6
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs
2020 · cited by 50
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs notes that small sample studies demonstrate interleukin-6 inhibitors may improve clinical outcomes in COVID-19.
See more details
More for · 5
Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
2021 · cited by 28
Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis reveals a significant reduction in mortality with tocilizumab and sarilumab.
Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review
2022 · cited by 27
Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review indicates that tocilizumab and other IL-6 inhibitors can reduce mortality in severe COVID-19 patients.
Outlook of IL-6 signaling blockade for COVID-19 pneumonia
2020 · cited by 22
Outlook of IL-6 signaling blockade for COVID-19 pneumonia discusses how IL-6 signal inhibitors provide efficacy in hospitalized populations when combined with standard of care.
Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19
2024 · cited by 3
Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19 states that blocking IL-6 is crucial for improving clinical outcomes and reducing death in severe COVID-19.
Rheumatic diseases and coronavirus infection: levilimab use experience
2021 · cited by 1
Rheumatic diseases and coronavirus infection: levilimab use experience confirms the high efficacy and good tolerability of IL-6 receptor inhibitors in treating coronavirus pneumonia.